Browse the evidence

Human hypothalamic melanocortin neurons (POMC and AgRP) exhibit significant transcriptomic and receptor-expression differences compared to mice, including species-specific GPCR profiles that directly impact the mechanism and efficacy of current obesity therapies.

Current obesity treatments like semaglutide and tirzepatide target the hypothalamus, but their exact molecular mechanisms in humans may differ from what we learned from mouse studies. This map reveals that human POMC neurons express different receptors (like CALCR) than mouse POMC neurons. This means drug developers must account for these human-specific differences to improve efficacy and reduce side effects, rather than relying solely on rodent data.

Absolute variance statistics (SDir, lnVR) are insufficient for detecting true interindividual response variation because they are confounded by mean-variance relationships (where higher means lead to higher variances); the Log Ratio of Coefficient of Variation (lnCVR) is required to isolate true response heterogeneity.

When evaluating resistance training results, do not assume that a wider range of outcomes (some people growing a lot, some a little) is solely due to individual 'trainability.' It may simply be that those who grew more had higher starting strengths, which naturally scale with greater variance. To truly understand why some people don't respond, you must look at relative variation (coefficient of variation) rather than absolute changes. For the individual, this means that 'average' program prescriptions will inevitably fail some people, not because the program is bad, but because biological scaling laws dictate that larger gains come with larger variance.

SGLT-2 inhibitors provide cardiovascular and renal protective benefits independent of their glucose-lowering effects, including reduced risk of heart failure hospitalization and worsening renal function.

SGLT-2 inhibitors (like Jardiance or Farxiga) are not just for blood sugar. They are now a standard treatment for heart failure and kidney disease, even in people without diabetes. They significantly reduce the risk of being hospitalized for heart failure and slow down kidney damage. If you have heart or kidney issues, ask your doctor if this class of medication is appropriate for you.

Estrogen therapy does not reduce cardiovascular disease events and may increase stroke risk in postmenopausal women, particularly those with diabetes, and is not recommended for chronic disease prevention.

Do not use estrogen to prevent heart disease. It does not work for this purpose and may increase stroke risk. If you have severe menopausal symptoms and are at low risk for other issues, it may be used for symptom relief, but risk calculators should guide this decision.

2'-FL supplementation does NOT significantly alter the Cytokine Response Score (CRS), a marker of immune aging, in older adults, despite increasing Bifidobacterium.

Taking 2'-FL (1g or 5g daily) for 6 weeks did not improve the Cytokine Response Score, a marker of immune aging, in older adults. However, it did increase Bifidobacterium and HDL cholesterol. Users should not expect this to reverse immune aging markers based on this study.

SGLT-2 inhibitors slow the progression of chronic kidney disease (CKD) and reduce the risk of end-stage kidney disease (ESKD) in patients with type 2 diabetes and albuminuria.

If you have diabetes and early kidney disease (albuminuria), SGLT-2 inhibitors (like Jardiance or Invokana) are recommended to protect your kidneys. They slow down the decline of kidney function and reduce the risk of needing dialysis, even if your blood sugar is already controlled.

SGLT-2 inhibitors reduce the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.

If you have heart failure with a weak pumping heart (HFrEF), SGLT-2 inhibitors (like Jardiance or Farxiga) are now a standard part of treatment. They reduce hospitalizations and death, even if you don't have diabetes. They help your heart pump more efficiently.

SGLT2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular death in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF), regardless of diabetes status.

If you have Heart Failure (whether your heart pumps strongly or weakly), SGLT2 inhibitors (Dapagliflozin or Empagliflozin) are a cornerstone treatment that reduces hospitalizations and death, even if you do not have Diabetes. Ask your cardiologist about these medications.

Secure multi-party computation (MPC) enables the linkage of patient data across different hospitals for research purposes without violating privacy regulations, allowing for accurate assessment of hospital transfer rates.

This paper is primarily for researchers and healthcare administrators. It demonstrates that advanced privacy-preserving technology (MPC) can be used to link patient data across hospitals, enabling more accurate research on patient outcomes and behaviors, such as hospital transfers.

Integrative computational modeling is required to understand the multiscale physiological responses to nutrition, bridging the gap between molecular mechanisms and whole-body metabolic syndrome outcomes.

To truly understand how diet affects health, especially for conditions like obesity and metabolic syndrome, we must move beyond simple statistics and use computational models that integrate data from genes to whole-body physiology. This approach allows us to predict how specific nutrients interact with biological systems over time.

Daily supplementation with 2000 IU of vitamin D or 1 g of marine n-3 fatty acids does not reduce the risk of major cardiovascular events, invasive cancer, or secondary outcomes in adults.

Do not take Vitamin D or Fish Oil supplements expecting them to prevent heart disease or cancer. Large studies show they do not work for this purpose at standard doses.

The American Heart Association's 2024 Statistical Update mandates the use of respectful, specific language for race and ethnicity (e.g., 'Black adults') rather than collective nouns (e.g., 'Blacks') to address health equity and structural racism.

When citing or writing about AHA data, use specific adjectives for race and ethnicity (e.g., 'Black adults') instead of collective nouns (e.g., 'Blacks'). This aligns with current scientific standards for equity and precision.

Lixisenatide, a GLP-1 receptor agonist, does not reduce the rate of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome compared to placebo.

If you have type 2 diabetes and have recently had a heart event, adding lixisenatide to your treatment plan will not lower your risk of another heart attack, stroke, or cardiovascular death compared to standard care alone. However, it does help lower blood sugar levels and may lead to modest weight loss. It is safe regarding serious adverse events like pancreatitis or cancer, but gastrointestinal issues like nausea are common reasons for stopping the drug.

Postmenopausal estrogen therapy does not reduce the risk of coronary heart disease and may increase it, contradicting observational data that suggested a protective effect.

If you are postmenopausal, do not take estrogen therapy solely to prevent heart disease. This paper demonstrates that it does not lower your risk of coronary heart disease and might actually increase it. Consult your doctor for other preventive strategies.

Current use of postmenopausal hormone therapy (estrogen alone or estrogen plus progestin) significantly increases the risk of invasive breast cancer, with the risk rising significantly after five or more years of use and being highest in women over age 55.

If you are a postmenopausal woman considering hormone therapy, be aware that current use of estrogen (alone or with progestin) increases breast cancer risk, especially if you are over 55 and use it for more than five years. Discuss these specific risks with your doctor to weigh them against potential benefits.

The increased risk of breast cancer mortality is associated with five or more years of postmenopausal hormone therapy, with a relative risk of death of 1.45.

Long-term use of estrogen (5+ years) is linked to a higher risk of dying from breast cancer. This underscores the importance of regular screening and discussing the duration of therapy with your doctor.

High dietary fiber intake does not reduce the risk of colorectal cancer or adenoma in women.

For women, increasing dietary fiber intake is unlikely to lower your risk of colorectal cancer or adenomas, despite common advice. This study suggests that other factors may be more critical for prevention.

GIP is the major physiological mediator of the incretin effect in healthy humans, contributing more to insulin secretion than GLP-1.

In healthy individuals, GIP is the primary driver of the 'incretin effect' (the boost in insulin after eating). This physiological fact underpins the rationale for using dual GIP/GLP-1 drugs in diabetes.

Beta-cell dysfunction and loss of functional mass are present at the time of Type 2 Diabetes diagnosis and progressively decline by approximately 5% annually, independent of disease duration.

Understand that beta-cell function naturally declines after diagnosis. This is not your fault, but it is a biological reality. The goal of management is to slow this decline by reducing the workload on your pancreas through weight management and lifestyle changes.

Consuming raw garlic or commercial garlic supplements (powdered or aged extract) at standard-to-high doses for 6 months does not produce statistically or clinically significant reductions in LDL-C or other plasma lipid concentrations in adults with moderate hypercholesterolemia.

If you have moderately high cholesterol, eating garlic or taking garlic supplements (raw, powdered, or aged extract) at typical doses will not significantly lower your LDL cholesterol. While garlic is a healthy food with other potential benefits, do not rely on it as a primary treatment for high cholesterol. Focus on proven lifestyle changes and medications if prescribed by your doctor.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, primarily through hemodynamic effects (osmotic diuresis and natriuresis) rather than glucose-lowering.

If you have Type 2 Diabetes and heart or kidney issues, SGLT2 inhibitors (like empagliflozin or dapagliflozin) are now considered a primary treatment option. They protect your heart and kidneys through fluid balance mechanisms, not just by lowering sugar. Discuss with your doctor if you are a candidate, especially if you have existing heart disease or kidney impairment.

Standardized validation protocols, including regular combustion or gas infusion tests, are required to ensure the accuracy and precision of whole-room indirect calorimetry systems for measuring human energy expenditure.

If you are using a whole-room calorimeter, you must validate its performance regularly using traceable standards (like combustion or gas infusion) and report these validation results (accuracy, precision, zero tests) in your publications. This ensures your energy expenditure data is comparable across studies and laboratories.

Intensive lifestyle intervention (ILI) does not significantly reduce the risk of major cardiovascular events (mortality, myocardial infarction, stroke) in adults with overweight/obesity and type 2 diabetes compared to standard diabetes support and education.

Even if lifestyle changes do not significantly lower your risk of heart attacks or death from cardiovascular causes, they still provide major benefits for your diabetes control, kidney health, and daily quality of life. The effort is still worthwhile for these other critical health improvements.

Data on dietary intakes for infants, young children, school-age children, older adults, and pregnant/lactating women is significantly sparse, with less than one-third of surveys including this information.

Recognize that dietary data for vulnerable populations (infants, children, older adults, pregnant/lactating women) is often missing. This limits our ability to assess their specific dietary needs and health risks accurately.